The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Open accessAbstract
INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). However, the mechanisms of resistance to these agents have not yet been described. METHODS: Analysis was performed of circulating tumor DNA and tissue in patients with RET fusion-positive NSCLC and RET-mutation positive MTC who developed disease progression after an initial response to selpercatinib. Acquired resistance was modeled preclinically using a CCDC6-RET fusion-positive NSCLC patient-derived xenograft. The inhibitory activity of anti-RET multikinase inhibitors and selective RET TKIs was evaluated in enzyme and cell-based assays. RESULTS: After a dramatic initial response to selpercatinib in a patient with KIF5B-RET NSCLC, analysis of circulating tumor DNA revealed emergence of RET G810R, G810S, and G810C mutations in the RET solvent front before the emergence of clinical resistance. Postmortem biopsy studies reported intratumor and intertumor heterogeneity with distinct disease subclones containing G810S, G810R, and G810C mutations in multiple disease sites indicative of convergent evolution on the G810 residue resulting in a common mechanism of resistance. Acquired mutations in RET G810 were identified in tumor tissue from a second patient with CCDC6-RET fusion-positive NSCLC and in plasma from patients with additional RET fusion-positive NSCLC and RET-mutant MTC progressing on an ongoing phase 1 and 2 trial of selpercatinib. Preclinical studies reported the presence of RET G810R mutations in a CCDC6-RET patient-derived xenograft (from a patient with NSCLC) model of acquired resistance to selpercatinib. Structural modeling predicted that these mutations sterically hinder the binding of selpercatinib, and in vitro assays confirmed loss of activity for both anti-RET multikinase inhibitors and selective RET TKIs. CONCLUSIONS: RET G810 solvent front mutations represent the first described recurrent mechanism of resistance to selective RET inhibition with selpercatinib. Development of potent inhibitor of these mutations and maintaining activity against RET gatekeeper mutations could be an effective strategy to target resistance to selective RET inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A hierarchical approach to all‐atom protein loop prediction
Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., & Friesner, R. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10613 · Cited by 2,504
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Self-citationGenomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Self-citationSelective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S., Smith, S., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 425
Self-citationYoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 294
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Self-citationRET rearrangements are actionable alterations in breast cancer
Paratala, B., Chung, J., Williams, C. B., Yilmazel, B., Petrosky, W., Williams, K. A., Schrock, A. B., Gay, L. M., Lee, E. C., Dolfi, S. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07341-4 · Cited by 135
Identification and characterization of RET fusions in advanced colorectal cancer
Rolle, A.-F. L., Klempner, S. J., Garrett, C. R., Seery, T. E., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4325 · Cited by 113
Gainor, J. F., Lee, K. H., Curigliano, G., Doebele, R. C., Kim, D., Baik, C. S., Tan, D. S.-W., Junior, G. L. L., Gadgeel, S. M., Cassier, P. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9008 · Cited by 112
Self-citationA secondary RET mutation in the activation loop conferring resistance to vandetanib
Nakaoku, T., Kohno, T., Araki, M., Niho, S., Chauhan, R., Knowles, P. P., Tsuchihara, K., Matsumoto, S., Shimada, Y., Mimaki, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02994-7 · Cited by 108
Ballerini, P. F., Struski, S., Cresson, C., Prade, N., Toujani, S., Deswarte, C., Dobbelstein, S., Petit, A., Lapillonne, H., Gautier, E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.109 · Cited by 107
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
Self-citationDrug resistance profiles of mutations in the RET kinase domain
Liu, X., Shen, T., Mooers, B. H. M., Hilberg, F., & Wu, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14395 · Cited by 100
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 77
Terzyan, S. S., Shen, T., Liu, X., Huang, Q., Teng, P., Zhou, M., Hilberg, F., Cai, J., Mooers, B. H. M., & Wu, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007682 · Cited by 61
Taylor, M. H., Gainor, J. F., Hu, M. I.-N., Zhu, V. W., Junior, G. L. L., Leboulleux, S., Brose, M. S., Schüler, M., Bowles, D. W., Kim, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6018 · Cited by 42
Self-citationWirth, L. J., Kohno, T., Udagawa, H., Matsumoto, S., Ishii, G., Ebata, K. T., Tuch, B. B., Zhu, E. Y., Nguyen, M., Smith, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00189 · Cited by 39
Self-citationRegistrational results of LOXO-292 in patients with RET-altered thyroid cancers
Wirth, L. J., Sherman, E. J., Drilon, A. E. D. C., Solomon, B., Robinson, B. G., Lorch, J. H., McCoach, C. E., Patel, J. D., Leboulleux, S., Worden, F. P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.093 · Cited by 27
Self-citationClinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma
O’Donnell, E., Mahindra, A. K., Yee, A. J., Nardi, V., Birrer, N., Horick, N., Borger, D. R., Finkelstein, D. M., Iafrate, J., & Raje, N. S. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.11.008 · Cited by 16
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 316
Metadata
- Authors
- Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., Oxnard, G. R., Gautschi, O., Drilon, A., Subbiah, V., Khoo, C., Zhu, E. Y., Nguyen, M., Henry, D., Condroski, K. R., Kolakowski, G. R., Gomez, E., Ballard, J., Metcalf, A. T., Blake, J. F., Dawson, S.-J., Blosser, W., Stancato, L. F., Brandhuber, B. J., Andrews, S., Robinson, B. G., & Rothenberg, S. M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 15
- Issue
- 4
- Pages
- 541-549
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3000979489
- Cited by
- 289
- References
- 22
- FWCI
- 22.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.